Novel Therapeutics for Advanced Differentiated Thyroid Cancer.

Leedor Lieberman, Francis Worden

Journal: Endocrinology and metabolism clinics of North America 2022;51(2):367-378

PMID: 35662446

Full Text on Elsevier Science View on PubMed

Abstract

The current treatments for radioactive iodine (RAI) -refractory differentiated thyroid cancer (DTC) are evolving as cancer genomics are further understood. Multitargeted tyrosine kinase inhibitors are the first-line therapy for symptomatic or progressive disease; however, considerable adverse effects have spurred the development of targeted therapies for redifferentiation of iodine avidity and the treatment of RAI-refractory DTC. Next-generation sequencing allows for the use of tumor-targeted therapeutics, such as MEK1/2, BRAF, RET, and NTRK inhibitors. Immunotherapy is also under investigation as a therapeutic option for this disease.

Address: Department of Metabolism, Endocrinology and Diabetes, University of Michigan, Lobby C #1300, 4029 Avenue Maria Drive, Ann Arbor, MI 48105, USA.; Department of Hematology and Oncology, University of Michigan, 1500 East Medical Center Drive Med Inn Building, Room C369, Ann Arbor, MI 48109, USA. Electronic address: [email protected].

DOI: 10.1016/j.ecl.2021.11.019